Daiwa Securities Group Inc. Increases Holdings in Edwards Lifesciences Corporation $EW

Daiwa Securities Group Inc. lifted its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 21.2% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 139,934 shares of the medical research company’s stock after purchasing an additional 24,475 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Edwards Lifesciences were worth $10,944,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Rosenberg Matthew Hamilton purchased a new position in Edwards Lifesciences during the 2nd quarter valued at about $28,000. Quantbot Technologies LP bought a new position in shares of Edwards Lifesciences in the first quarter valued at approximately $26,000. NewSquare Capital LLC boosted its position in shares of Edwards Lifesciences by 57.8% in the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 134 shares during the period. SouthState Corp purchased a new position in Edwards Lifesciences during the first quarter valued at approximately $27,000. Finally, Atlantic Union Bankshares Corp bought a new stake in Edwards Lifesciences during the 2nd quarter worth approximately $40,000. Institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Jefferies Financial Group set a $98.00 price target on shares of Edwards Lifesciences and gave the company a “buy” rating in a report on Wednesday, October 29th. Barclays reiterated an “overweight” rating and issued a $103.00 price objective (up previously from $99.00) on shares of Edwards Lifesciences in a research report on Monday. Evercore ISI boosted their target price on Edwards Lifesciences from $88.00 to $92.00 and gave the stock an “outperform” rating in a research report on Friday, October 31st. Truist Financial set a $92.00 price target on Edwards Lifesciences and gave the company a “hold” rating in a report on Friday, December 5th. Finally, National Bankshares set a $92.00 price target on Edwards Lifesciences in a research report on Friday, October 31st. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $93.09.

Edwards Lifesciences Price Performance

EW opened at $83.97 on Thursday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29. The stock’s 50 day simple moving average is $81.34 and its 200 day simple moving average is $78.92. The firm has a market cap of $48.73 billion, a price-to-earnings ratio of 36.19, a PEG ratio of 3.74 and a beta of 0.97. Edwards Lifesciences Corporation has a 1 year low of $65.94 and a 1 year high of $87.89.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.08. The firm had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.During the same quarter in the previous year, the company posted $0.67 earnings per share. The business’s revenue was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,700 shares of the firm’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total value of $650,419.00. Following the sale, the chief financial officer owned 39,898 shares of the company’s stock, valued at $3,370,184.06. This trade represents a 16.18% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Daniel J. Lippis sold 1,020 shares of the business’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $82.55, for a total transaction of $84,201.00. Following the completion of the transaction, the vice president owned 22,002 shares in the company, valued at $1,816,265.10. The trade was a 4.43% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 33,060 shares of company stock valued at $2,765,292 in the last quarter. Company insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.